In Brief
Refine Search
Pharmaceutical
USA-based Acadia Pharmaceuticals has expanded its current licensing agreement for trofinetide with Australian biotech Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. 15 July 2023
Pharmaceutical
Sweden's Vicore Pharma will install Ahmed Mousa as chief executive, replacing outgoing CEO Carl-Johan Dalsgaard, who is retiring. 14 July 2023
Pharmaceutical
German drugmaker STADA Arzneimittel is significantly expanding its European Consumer Healthcare portfolio by acquiring another range of well-established and leading local and regional consumer healthcare brands from French pharma major Sanofi in European countries. 13 July 2023
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm has established outposts in Brazil and Mexico, as part of its strategy to globalize its operations outside Europe. 12 July 2023
Pharmaceutical
Swedish enzyme technology firm Hansa Biopharma announced that the Australian Therapeutic Goods Administration (TGA) has provisionally approved Idefirix (imlifidase) as desensitization treatment for highly sensitized patients prior to kidney transplantation from both living and deceased donors. 11 July 2023
Pharmaceutical
Switzerland-headquartered Idorsia and its US subsidiary today announced that, effective immediately, pharmacy benefit managers (PBM) CVS is covering Quviviq (daridorexant) CIV on the Performance Drug List (PDL). 10 July 2023
Pharmaceutical
Cambridge, UK-based Metrion Biosciences, a specialist ion channel contract research and drug discovery company, today announced the appointments of Dr Robert Kirby to chief operating officer and Dr Edward Stevens to chief scientific officer. 6 July 2023
Pharmaceutical
The USA’s Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of xanomeline tartrate/trospium chloride, known as KarXT, from Karuna Therapeutics, for the treatment of schizophrenia. 5 July 2023
Pharmaceutical
Japanese drugmaker Eisai has entered into an agreement to transfer all future economic rights for elacestrant, approved for the treatment for breast cancer in the USA, to Canada-headquartered DRI Healthcare Trust. 3 July 2023
Pharmaceutical
Tonix Pharmaceuticals is to buy two marketed acute migraine products from Upsher-Smith Laboratories - Zembrace SymTouch (sumatriptan) and Tosymra (sumatriptan) . 27 June 2023
Pharmaceutical
Japanese pharma major Chugai Pharmaceutical says it will establish a corporate venture capital (CVC) business, under the tentative name “Chugai Venture Fund,” in the Boston area, USA, by the end of 2023 to invest in innovative drug discovery start-up companies to accelerate innovation opportunities centered on innovative new drugs. 27 June 2023
Pharmaceutical
Today, the US Food and Drug Administration published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including psychiatric or substance use disorders. 23 June 2023
Pharmaceutical
The US Food and Drug Administration has approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes 21 June 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk has warned that the launch of its weight management drug Wegovy (semaglutide) in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, as demand booms in the USA. 21 June 2023
Pharmaceutical
UK pharma major AstraZeneca has drafted plans to break out its China business and list it as a separate company in Hong Kong, or maybe Shanghai, as a way of protecting the company from geopolitical tensions, according to a report by the Financial Times this morning. 19 June 2023
Pharmaceutical
The Prescription Medicines Code of Practice Authority (PMCPA), a division of the UK’s leading pharmaceutical trade body, has issued notices against a number of drugmakers for breaking the code of practice. 16 June 2023
Pharmaceutical
Danish dermatology specialist LEO Pharma has today announced that its new UK and Ireland operational headquarters will be based at Foundation Park, a new leading business campus in Maidenhead, some 30 miles west of London. 16 June 2023
Pharmaceutical
The US District Court for the District of Delaware has issued a decision finding that Japanese drug major Astellas Pharma’s US Patent No 10,842 on Myrbetriq (mirabegron), which expires in March 2030, is invalid, the company confirmed today. 12 June 2023
Pharmaceutical
Australia’s Therapeutic Goods Administration (TGA) has issued five infringement notices totalling A$66,600 ($45,000) to Affinity Corp Australia for the alleged unlawful advertising of medicinal cannabis products. 12 June 2023
Pharmaceutical
As part of its ongoing study on pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the USA’s Federal Trade Commission (FTC) has issued a compulsory order to a third group purchasing organization (GPO) that negotiates drug rebates on behalf of PBMs. 9 June 2023
Pharmaceutical
The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson, for some adult patients in England. 10 April 2025
Pharmaceutical
At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation associated with Alzheimer’s disease (AD). 10 April 2025
Pharmaceutical
The first comprehensive analysis of clinical trials in the UK has found the country remains a global leader in medical research but highlights the need for broader disease focus and better trial representation. 10 April 2025
Pharmaceutical
Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s Montes Claros, northern Minas Gerais, with the aim of increasing production capacity for injectable treatments for people with obesity, diabetes and other serious chronic diseases. 10 April 2025
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (CER), in collaboration with researchers from Brown University, has published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications. 10 April 2025
Pharmaceutical
The All-Russian Union of Patients (VSP) has called on Russia’s Deputy Prime Minister, Tatyana Golikova, to expand the list of drugs that are the subject of public procurements in the country in order to avoid a shortage of certain categories of drugs in the domestic market, The Pharma Letter’s local correspondent reports.. 10 April 2025
Pharmaceutical
The Russian pharmaceutical market grew by 10% in value terms to 2.85 trillion roubles ($85 billion) in 2024, which was mainly due to the growth of it commercial segment, where the growth of sales was equivalent to 13.8%. 9 April 2025
Pharmaceutical
The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma major AbbVie , for the treatment of giant cell arteritis (GCA) in adult patients. 9 April 2025
Pharmaceutical
US biotech Annovis Bio has reported encouraging findings for its experimental therapy buntanetap in a subgroup of patients with early-stage Parkinson’s disease and mild dementia. 9 April 2025
Pharmaceutical
Swiss biopharma Idorsia has received approval from the US Food and Drug Administration for an updated label on its hypertension drug Tryvio (aprocitentan), removing the previous Risk Evaluation and Mitigation Strategy requirement. 9 April 2025
Pharmaceutical
Shares of USA and UK-based KalVista Pharmaceuticals fell 4% to $11.04 yesterday, despite the company revealing it has signed a licensing deal for the commercialization rights in Japan to Kaken Pharmaceutical for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). 9 April 2025
Pharmaceutical
The uveitis treatment market across seven major markets—the USA, France, Germany, Italy, Spain, the UK, and Japan—is projected to grow from $522 million in 2023 to $1.5 billion by 2033, according to a report from data analytics firm GlobalData. This marks an annual growth rate of nearly 11%. 8 April 2025
Pharmaceutical
In the USA, the layoffs at health agencies, proposed tariffs on imports and other disruptive policies under President Donald Trump have led some to express concern over a potential ‘brain drain’ impacting pharma and other industries. 8 April 2025
Pharmaceutical
US biopharma Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase III TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity. 8 April 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical Industries revealed it has launched fexuprazan tablets 40mg in India under the brand name Fexuclue, which is a novel potassiumcompetitive acid blocker (PCAB) that is approved as a new treatment for adults with erosive esophagitis of all grades. 8 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in development for early PD, failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy. 8 April 2025
Pharmaceutical
US biotech company Vertex Pharmaceuticals has received European Commission approval to extend the use of its cystic fibrosis therapy, Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with ivacaftor. 8 April 2025
Pharmaceutical
The USA’s Centers for Medicare & Medicaid Services (CMS) yesterday released the Calendar Year (CY) 2026 Rate Announcement for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs that finalizes the payment policies for these programs. 8 April 2025
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze